• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆碱能控制纹状体神经元以调节左旋多巴诱导的运动障碍。

Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias.

机构信息

Center for Health Sciences, SRI International, 333 Ravenswood Ave, Menlo Park, CA, 94025, USA.

出版信息

Eur J Neurosci. 2019 Mar;49(6):859-868. doi: 10.1111/ejn.14048. Epub 2018 Jul 21.

DOI:10.1111/ejn.14048
PMID:29923650
Abstract

L-dopa induced dyskinesias (LIDs) are a disabling motor complication of L-dopa therapy for Parkinson's disease (PD) management. Treatment options remain limited and the underlying network mechanisms remain unclear due to a complex pathophysiology. What is well-known, however, is that aberrant striatal signaling plays a key role in LIDs development. Here, we discuss the specific contribution of striatal cholinergic interneurons (ChIs) and GABAergic medium spiny projection neurons (MSNs) with a particular focus on how cholinergic signaling may integrate multiple striatal systems to modulate LIDs expression. Enhanced ChI transmission, altered MSN activity and the associated abnormal downstream signaling responses that arise with nigrostriatal damage are well known to contribute to LIDs development. In fact, enhancing M4 muscarinic receptor activity, a receptor favorably expressed on D1 dopamine receptor-expressing MSNs dampens their activity to attenuate LIDs. Likewise, ChI activation via thalamostriatal neurons is shown to interrupt cortical signaling to enhance D2 dopamine receptor-expressing MSN activity via M1 muscarinic receptors, which may interrupt ongoing motor activity. Notably, numerous preclinical studies also show that reducing nicotinic cholinergic receptor activity decreases LIDs. Taken together, these studies indicate the importance of cholinergic control of striatal neuronal activity and point to muscarinic and nicotinic receptors as significant pharmacological targets for alleviating LIDs in PD patients.

摘要

左旋多巴诱导的运动障碍(LIDs)是左旋多巴治疗帕金森病(PD)管理的一种致残性运动并发症。由于复杂的病理生理学,治疗选择仍然有限,潜在的网络机制仍不清楚。然而,众所周知的是,纹状体信号异常在 LIDs 的发展中起着关键作用。在这里,我们讨论了纹状体胆碱能中间神经元(ChIs)和 GABA 能中间神经元(MSNs)的特定贡献,特别关注胆碱能信号如何整合多个纹状体系统来调节 LIDs 的表达。增强 ChI 传递、改变 MSN 活性以及与黑质纹状体损伤相关的异常下游信号反应,这些都被认为是 LIDs 发展的原因。事实上,增强 M4 毒蕈碱受体活性,这种受体在表达 D1 多巴胺受体的 MSN 上表达良好,可抑制其活性以减轻 LIDs。同样,通过丘脑纹状体神经元激活 ChI 被证明可以中断皮质信号,通过 M1 毒蕈碱受体增强表达 D2 多巴胺受体的 MSN 活性,从而中断正在进行的运动活动。值得注意的是,许多临床前研究还表明,降低烟碱型胆碱能受体活性可减少 LIDs。综上所述,这些研究表明了纹状体神经元活动的胆碱能控制的重要性,并指出毒蕈碱和烟碱受体是缓解 PD 患者 LIDs 的重要药理学靶点。

相似文献

1
Cholinergic control of striatal neurons to modulate L-dopa-induced dyskinesias.胆碱能控制纹状体神经元以调节左旋多巴诱导的运动障碍。
Eur J Neurosci. 2019 Mar;49(6):859-868. doi: 10.1111/ejn.14048. Epub 2018 Jul 21.
2
Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease.纹状体胆碱能中间神经元以及M1和M4毒蕈碱受体在帕金森病运动症状中的作用
J Neurosci. 2016 Aug 31;36(35):9161-72. doi: 10.1523/JNEUROSCI.0873-16.2016.
3
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.纹状体胆碱能中间神经元的光遗传学激活可调节左旋多巴诱发的运动障碍。
Neurobiol Dis. 2016 Jul;91:47-58. doi: 10.1016/j.nbd.2016.02.019. Epub 2016 Feb 24.
4
The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease.纹状体中中棘神经元和胆碱能中间神经元在 D₂/A₂A 受体相互作用中的独特作用:对帕金森病的影响。
J Neurosci. 2011 Feb 2;31(5):1850-62. doi: 10.1523/JNEUROSCI.4082-10.2011.
5
The striatal cholinergic system in L-dopa-induced dyskinesias.纹状体胆碱能系统在左旋多巴诱导的运动障碍中的作用。
J Neural Transm (Vienna). 2018 Aug;125(8):1251-1262. doi: 10.1007/s00702-018-1845-9. Epub 2018 Feb 28.
6
Selective activation of striatal indirect pathway suppresses levodopa induced-dyskinesias.选择性激活纹状体间接通路抑制左旋多巴诱导的运动障碍。
Neurobiol Dis. 2023 Jan;176:105930. doi: 10.1016/j.nbd.2022.105930. Epub 2022 Nov 19.
7
Chemogenetic modulation of cholinergic interneurons reveals their regulating role on the direct and indirect output pathways from the striatum.化学遗传学调节胆碱能中间神经元揭示了它们对纹状体直接和间接输出通路的调节作用。
Neurobiol Dis. 2018 Jan;109(Pt A):148-162. doi: 10.1016/j.nbd.2017.10.010. Epub 2017 Oct 14.
8
Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease.胆碱能中间神经元对帕金森病纹状体病理生理学的贡献。
Neurochem Int. 2019 Jun;126:1-10. doi: 10.1016/j.neuint.2019.02.019. Epub 2019 Feb 27.
9
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.纹状体D1中等棘状神经元激活在帕金森病小鼠中诱发运动障碍。
Mov Disord. 2017 Apr;32(4):538-548. doi: 10.1002/mds.26955. Epub 2017 Mar 3.
10
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.L-DOPA 治疗选择性地恢复了运动障碍小鼠中表达多巴胺受体 D2 的投射神经元中的棘密度。
Biol Psychiatry. 2014 May 1;75(9):711-22. doi: 10.1016/j.biopsych.2013.05.006. Epub 2013 Jun 13.

引用本文的文献

1
Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input.多巴胺和兴奋性突触输入控制与舞蹈病相关的纹状体直接通路神经元的过度放电。
Cell Rep. 2024 Aug 27;43(8):114483. doi: 10.1016/j.celrep.2024.114483. Epub 2024 Jul 17.
2
Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.左旋多巴诱导的帕金森病运动障碍:发病机制与新兴治疗策略。
Cells. 2022 Nov 23;11(23):3736. doi: 10.3390/cells11233736.
3
Cholinergic Receptor Modulation as a Target for Preventing Dementia in Parkinson's Disease.
胆碱能受体调节作为预防帕金森病痴呆的靶点
Front Neurosci. 2021 Sep 20;15:665820. doi: 10.3389/fnins.2021.665820. eCollection 2021.
4
Novel Pharmacotherapies in Parkinson's Disease.帕金森病的新型药物治疗。
Neurotox Res. 2021 Aug;39(4):1381-1390. doi: 10.1007/s12640-021-00375-5. Epub 2021 May 18.
5
Circuit Mechanisms of L-DOPA-Induced Dyskinesia (LID).左旋多巴诱发异动症(LID)的环路机制
Front Neurosci. 2021 Mar 10;15:614412. doi: 10.3389/fnins.2021.614412. eCollection 2021.
6
Neurobiological mechanisms associated with antipsychotic drug-induced dystonia.与抗精神病药引起的张力障碍相关的神经生物学机制。
J Psychopharmacol. 2021 Jan;35(1):3-14. doi: 10.1177/0269881120944156. Epub 2020 Sep 9.
7
Striatal Dopamine D-Muscarinic Acetylcholine M Receptor-Receptor Interaction in a Model of Movement Disorders.运动障碍模型中纹状体多巴胺 D 型与毒蕈碱型乙酰胆碱 M 受体的相互作用
Front Pharmacol. 2020 Mar 13;11:194. doi: 10.3389/fphar.2020.00194. eCollection 2020.
8
Managing Parkinson's disease: moving ON with NOP.管理帕金森病:与 NOP 一起前行。
Br J Pharmacol. 2020 Jan;177(1):28-47. doi: 10.1111/bph.14893. Epub 2020 Jan 3.
9
Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.锥体外系运动障碍的神经病理学和发病机制:批判性更新-I. 运动减少-僵硬的运动障碍。
J Neural Transm (Vienna). 2019 Aug;126(8):933-995. doi: 10.1007/s00702-019-02028-6. Epub 2019 Jun 18.
10
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.受体配体在治疗帕金森病中作为左旋多巴的辅助手段。
Biomolecules. 2019 Apr 9;9(4):142. doi: 10.3390/biom9040142.